On April 4, Huitai Medical (688617. SH) announced that Han Yonggui, deputy general manager of the company, holds 124,400 shares of the company, accounting for 0.1281% of the company's current total share capital. Han Yonggui intends to reduce his holdings through centralized bidding and block trading, with a total of no more than 30,000 shares, that is, no more than 0.0309% of the company's total share capital.

Since the beginning of this year, Huitai Medical's share price has risen, with a 11.43% increase for the year as of April 3.

On February 24, Huitai Medical released its 2024 performance report, and the company's operating income in 2024 was 2.066 billion yuan, a year-on-year increase of 25.18%; The corresponding attributable net profit was 673 million yuan, a year-on-year increase of 26.14%.

Huitai Medical pointed out that during the reporting period, the company continued to deepen market development, continued to carry out various marketing activities, actively gave full play to its business advantages in R&D, technology, quality, market, channels and other aspects, continuously deepened channel linkage, and further improved product coverage and hospital admission rate. Actively expand overseas markets and continue to increase investment in international business.

However, compared with the rapid growth in previous years, Huitai Medical's growth rate began to slow down significantly, with the company's net profit increasing by 49.13% year-on-year in 2023, 72.19% year-on-year in 2022, and 86.47% year-on-year in 2021.

In 2024, the growth rate will be low for four consecutive quarters, with a net profit increase of 36.48% year-on-year in the first quarter, a 33% year-on-year increase in net profit in the semi-annual report, a 31% year-on-year increase in net profit in the third quarter, and a 26% increase in the annual report, which means that the performance growth in the fourth quarter is limited.

According to public information, Huitai Medical is deeply engaged in the field of interventional high-value medical devices, and its main products cover the cardiac and peripheral interventional markets, and its subsidiary Hunan Epte focuses on coronary and peripheral vascular products. On August 26 last year, the National Health Insurance Administration announced the results of the price reduction of thoracic aortic stent grafts of enterprises, and the price of Hunan Epte stent was limited to 78,000 yuan and below.

On January 28, 2024, Mindray Medical and Huitai Medical announced that the former would acquire the control of Huitai Medical with its own funds of 6.65 billion yuan through the method of "transfer by agreement + waiver of voting rights by the original actual controller". With the completion of Mindray's acquisition of Huitai Medical, the actual controllers of Huitai Medical have been changed to Li Xiting and Xu Hang, who are the chairman and director of Mindray Medical, respectively.